Boston Scientific Falls on Sales Hit After August Cyberattack

Boston Scientific Corp. cut its sales forecast, citing a cyberattack in August that disrupted operations. It now expects Q4 sales to decline and full-year adjusted EPS of $3.16-$3.18, below analysts' estimate of $3.23. Shares fell 14% in premarket trading.

Original reporting
Published Oct 28, 2026, 12:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BSX
Bearish
high confidence
Mentioned
$BSX
Relevance
8/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The guidance cut and immediate share decline suggest heightened short‑term risk for the stock.

02

Market read

First‑report of a material guidance downgrade for a large‑cap med‑tech firm, driving a notable pre‑market price drop.

03

What to watch

Potential insurance recoveries or cost‑saving measures post‑attack could mitigate earnings hit.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Boston Scientific disclosed a cyberattack that disrupted operations and prompted a downgrade of its full‑year sales outlook and earnings guidance.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific lowered its full-year adjusted EPS to $3.16‑$3.18 and warned Q4 sales will decline, sending the stock down as much as 14% pre‑market.

Expected impact

likely further downside as investors price in weaker outlook

Evidence & confidence

Guidance revisions are material for a large‑cap med‑tech firm and the stock already fell 14% on the news.

Market effects

May weigh on other med‑device peers as investors reassess demand amid cyber‑risk concerns.

Limited to U.S. markets; no broader regional effect noted.

Modest; primarily a company‑specific catalyst.

Counterpoint

If the cyberattack impact is short‑lived, the stock could rebound once operations normalize.

Key entities

  • Boston Scientific Corp.

    Medical device maker reporting weaker guidance after a cyberattack.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.